SLC5A2 and type 2 diabetes mellitus: Dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor (GLP-1R) agonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors have been rigorously evaluated through cardiovascular outcomes trials in the management of type 2 diabetes.